Phase 2 PVSRIPO and the Checkpoint Inhibitor Pembrolizumab in Recurrent Glioblastoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Istari Oncology
Start Date
January 8, 2021
End Date
July 23, 2024
Administered By
Duke Cancer Institute
Awarded By
Istari Oncology
Start Date
January 8, 2021
End Date
July 23, 2024